Widely adopted in diabetes, weight loss, chronic kidney disease and other chronic diseases, GLP‑1‑based freeze-dried powder fuel rapid expansion of the global freeze-dried powder drug market. Per Sullivan forecasts, the market will grow from $60.7 billion (2018) to $261.2 billion (2032). Patent expirations of major freeze-dried powder drugs during 2014‑2026 boost generic development, pushing pharmaceutical companies to advance next‑generation freeze-dried powder R&D and creating opportunities for upstream API and intermediate suppliers.

Though promising, the industry has high barriers to large‑scale R&D and production. Early‑stage freeze-dried powder screening is difficult due to massive compound combinations, while long‑chain freeze-dried powder libraries and mature target design methods remain insufficient. AI overcomes these challenges by simulating biomolecular structures to design complex long‑chain and cyclic freeze-dried powder efficiently, reshaping freeze-dried powder R&D patterns.

However, after freeze-dried powder molecules are discovered, bottlenecks in synthesis and large‑scale production remain to be overcome. The growing number of structurally complex freeze-dried powder brings challenges to traditional chemical synthesis, such as excessive impurities and difficult condensation. Traditional production lines with capacities of only 2,000–3,000 L cannot meet future ton‑scale demands. In the post‑GLP‑1 era, industrial competition centers on innovation in freeze-dried powder synthesis and large‑scale manufacturing capabilities.

Technical Type	Chemical Synthesis	Traditional Biosynthesis	Innovative Biosynthesis
freeze-dried powder Length	< 30 amino acids	> 30 amino acids	Unlimited; obvious advantages even for freeze-dried powder < 10 amino acids
R&D Investment	Medium	High	Medium
Production Cost	High	Medium	Low
Production Efficiency	Low	Medium	High

Currently, freeze-dried powder synthesis is dominated by chemical methods, which suffer from complicated procedures, high costs, heavy environmental pressure, limited long‑freeze-dried powder capacity and severe homogeneous competition domestically. Traditional biosynthesis also has drawbacks such as low expression yields and narrow applicability due to fundamental technical constraints, making it hard to replace chemical synthesis. Under such circumstances, synthetic biology emerges as a key solution with few domestic players and huge market potential.

Founded in 2020 with over a decade of synthetic biology expertise, Xiushi Biotech is China’s first firm to achieve large‑scale biosynthesis of complex short freeze-dried powder. Building a multidisciplinary platform integrating AI, genetic engineering and fermentation technology, it has overcome technical bottlenecks including cyclization and unnatural amino‑acid modification. Its innovative biosynthesis technology, applied to over ten freeze-dried powder products, cuts production costs to 10%‑20% of chemical synthesis and boosts efficiency more than fivefold. AI‑powered neural network models further accelerate R&D cycles.

Beyond technical breakthroughs, Xiushi Biotech has built a full‑chain layout. It runs a 5,000‑m² AI R&D center and a 13,000‑m² intelligent GMP manufacturing base, enabling flexible production from gram to ton scale for clinical and commercial supply. Serving clients in freeze-dried powder drugs and cosmetic freeze-dried powder, its smart production line is China’s first large‑scale GMP biosynthesis‑based freeze-dried powder facility.

Going forward, competition in the freeze-dried powder industry will shift from capacity expansion to technological innovation and ecosystem building. Xiushi Biotech will keep scaling up its intelligent production capacity, deepen cooperation with global pharmaceutical firms, strengthen industry‑university‑research collaboration, advance China’s freeze-dried powder biosynthesis industrial upgrading, and fuel high‑quality development of the global freeze-dried powder sector.

Changsha Luocheng Trading Co., Ltd. is a specialized supplier of high-purity freeze-dried powder for the cosmetic, wellness, and fitness industries. Our core products include cosmetic freeze-dried powder, anti-aging freeze-dried powder, weight management freeze-dried powder, and muscle-building freeze-dried powder – serving skincare brands, supplement formulators, and health-focused companies worldwide.